Filana Therapeutics, Inc. (FLNA): Capital Expenditures
$581.0K
Year ended 2025-12-31
-40.2%
3-year compound annual growth
+11.5%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $581.0K | +464.1% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $103.0K | -75.1% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $414.0K | -84.7% | 2026-03-12, From 2023-01-01 |
| 2022-12-31 | $2.71M | -87.8% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $22.21M | n/a | 2024-02-28, From 2021-01-01 |
| No annual figure between 2019-12-31 and 2021-12-31. | |||
| 2019-12-31 | $18.0K | n/a | 2021-03-23, From 2019-01-01 |
| No annual figure between 2016-12-31 and 2019-12-31. | |||
| 2016-12-31 | $75.0K | -61.5% | 2018-02-06, From 2016-01-01 |
| 2015-12-31 | $195.0K | +143.8% | 2017-03-07, From 2015-01-01 |
| 2014-12-31 | $80.0K | n/a | 2017-03-07, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $581.0K | +464.1% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $279.0K | -36.7% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $95.0K | -12.8% |
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $38.0K | -85.7% |
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $29.0K | -95.6% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $4.0K | -97.2% |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $302.0K | +815.2% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $518.0K | -97.1% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $567.0K | -89.1% |
Compare FLNA, CAMP, AARD, KYNB side by side · Screen every company in Pharmaceutical Preparations ↗